First do no harm: extending the debate on the provision of preventive tamoxifen

The Breast Cancer Prevention Trial (BCPT-P-1) demonstrated that tamoxifen could reduce the risk of invasive breast cancer in high-risk women by 49%, but that it could also increase the risk of endometrial cancer, vascular events and cataracts. This paper provides an estimate of the net health impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Will, B P, Nobrega, K M, Berthelot, J-M, Flanagan, W, Wolfson, M C, Logan, D M, Evans, W K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375241/
https://www.ncbi.nlm.nih.gov/pubmed/11720461
http://dx.doi.org/10.1054/bjoc.2001.2125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375241/
https://www.ncbi.nlm.nih.gov/pubmed/11720461
http://dx.doi.org/10.1054/bjoc.2001.2125

Ejemplares similares